Compare Biocon with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NOVARTIS - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NOVARTIS BIOCON /
NOVARTIS
 
P/E (TTM) x 33.1 1,964.2 1.7% View Chart
P/BV x 3.9 26.1 15.1% View Chart
Dividend Yield % 0.2 1.7 14.7%  

Financials

 BIOCON    NOVARTIS
EQUITY SHARE DATA
    BIOCON
Mar-19
NOVARTIS
Mar-19
BIOCON /
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs707980 72.2%   
Low Rs554600 92.3%   
Sales per share (Unadj.) Rs91.9198.7 46.2%  
Earnings per share (Unadj.) Rs16.721.0 79.7%  
Cash flow per share (Unadj.) Rs24.222.3 108.6%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.3 12.5%  
Book value per share (Unadj.) Rs101.6307.5 33.1%  
Shares outstanding (eoy) m600.0024.69 2,430.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.0 172.6%   
Avg P/E ratio x37.737.7 100.1%  
P/CF ratio (eoy) x26.135.5 73.5%  
Price / Book Value ratio x6.22.6 241.5%  
Dividend payout %6.047.7 12.5%   
Avg Mkt Cap Rs m378,33019,508 1,939.4%   
No. of employees `0006.10.6 1,055.2%   
Total wages/salary Rs m11,6531,171 995.0%   
Avg. sales/employee Rs Th8,994.38,445.4 106.5%   
Avg. wages/employee Rs Th1,900.72,015.7 94.3%   
Avg. net profit/employee Rs Th1,635.3891.0 183.5%   
INCOME DATA
Net Sales Rs m55,1444,907 1,123.8%  
Other income Rs m1,444783 184.5%   
Total revenues Rs m56,5885,689 994.6%   
Gross profit Rs m15,883123 12,934.0%  
Depreciation Rs m4,47832 14,081.8%   
Interest Rs m70916 4,459.1%   
Profit before tax Rs m12,140858 1,415.4%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123340 624.4%   
Profit after tax Rs m10,026518 1,936.6%  
Gross profit margin %28.82.5 1,150.9%  
Effective tax rate %17.539.6 44.1%   
Net profit margin %18.210.6 172.3%  
BALANCE SHEET DATA
Current assets Rs m48,2288,055 598.8%   
Current liabilities Rs m30,3761,850 1,641.9%   
Net working cap to sales %32.4126.4 25.6%  
Current ratio x1.64.4 36.5%  
Inventory Days Days6845 151.7%  
Debtors Days Days8634 252.1%  
Net fixed assets Rs m64,130150 42,810.4%   
Share capital Rs m3,000123 2,431.1%   
"Free" reserves Rs m57,9807,469 776.3%   
Net worth Rs m60,9807,592 803.2%   
Long term debt Rs m15,7660-   
Total assets Rs m121,9249,824 1,241.0%  
Interest coverage x18.154.9 33.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 90.6%   
Return on assets %8.85.4 162.1%  
Return on equity %16.46.8 241.1%  
Return on capital %16.811.5 145.6%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50658 26,920.1%   
Fx outflow Rs m10,3991,326 784.1%   
Net fx Rs m5,107-1,269 -402.5%   
CASH FLOW
From Operations Rs m11,546-1,943 -594.3%  
From Investments Rs m-7,1382,742 -260.3%  
From Financial Activity Rs m-2,417-298 810.5%  
Net Cashflow Rs m2,103501 419.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 2.0 420.0%  
FIIs % 10.7 1.6 668.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.5 92.6%  
Shareholders   109,995 41,647 264.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 20, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS